Trial Profile
Phase II study of skin toxicity dosing of IRESSA (gefitinib) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2006
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 21 Dec 2006 Status change
- 07 Dec 2006 New trial record.